Abstract
Cancer is a complex disease that often eludes successful treatment due to its propensity to evolve or adapt in the face of current therapeutic regimes. It is reasonable to suggest that sophisticated therapeutics that can attack cancers in multiple, but targeted ways, will be necessary in order to improve current success rates. It is the thesis of this article that Oncolytic Viruses (OVs), are a new generation of “smart therapeutics” for cancer with tremendous potential to revolutionize the management of what has become one of mankinds scourges. A number of viruses are being developed around the world for this purpose (one has already been approved for human use in China [1]) and I propose that it is now essential to embrace the technology and use our recent and evolving understanding of the molecular biology of cancer to fully exploit the oncolytic virus platform. In the remainder of this article I speculate on some of the next important steps in OV development and directions the platform may be headed in the future.
Keywords: GFP gene, through-put sequencing, antitumour immunity, signaling pathway, Oncogenic mutations
Current Cancer Drug Targets
Title: Oncolytic Viruses: Whats Next?
Volume: 7 Issue: 2
Author(s): John C. Bell
Affiliation:
Keywords: GFP gene, through-put sequencing, antitumour immunity, signaling pathway, Oncogenic mutations
Abstract: Cancer is a complex disease that often eludes successful treatment due to its propensity to evolve or adapt in the face of current therapeutic regimes. It is reasonable to suggest that sophisticated therapeutics that can attack cancers in multiple, but targeted ways, will be necessary in order to improve current success rates. It is the thesis of this article that Oncolytic Viruses (OVs), are a new generation of “smart therapeutics” for cancer with tremendous potential to revolutionize the management of what has become one of mankinds scourges. A number of viruses are being developed around the world for this purpose (one has already been approved for human use in China [1]) and I propose that it is now essential to embrace the technology and use our recent and evolving understanding of the molecular biology of cancer to fully exploit the oncolytic virus platform. In the remainder of this article I speculate on some of the next important steps in OV development and directions the platform may be headed in the future.
Export Options
About this article
Cite this article as:
Bell C. John, Oncolytic Viruses: Whats Next?, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058844
DOI https://dx.doi.org/10.2174/156800907780058844 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets The Role of Saffron in Attenuating Age-related Oxidative Damage in Rat Hippocampus
Recent Patents on Food, Nutrition & Agriculture Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety The Tumor Suppressor Role of the Ras Association Domain Family 10
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets 18F-Labeled Proteins
Current Pharmaceutical Biotechnology Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Spontaneous Pneumothorax
Current Respiratory Medicine Reviews Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology “Cancer Antigen WT1 Protein-Derived Peptide”-Based Treatment of Cancer -Toward the Further Development
Current Medicinal Chemistry Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results
Current Cancer Drug Targets